Two bills aim to close gaps and ensure equitable access by requiring private health insurance coverage of FDA-approved ...
The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...
Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...
So, what’s really going on? In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company ...
Pharmaceutical Technology on MSN7d
UK’s pricing watchdog rejects Alzheimer treatments for the second timeThe UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...
A special edition of the journal Science focuses on women's health, including links between estrogen and dementia, at a time ...
It's hard to trust the disease statistics when cognitive tests often are not completed, write Robert Brownell and Dr. Yogesh ...
FOX 13 Tampa Bay on MSN3d
Ironman athlete diagnosed with Alzheimer’s focuses on new finish line: ‘A time for hope’The Ironman Triathlon is a grueling 140 miles, which includes a 2.4-mile swim, a 112-mile bike ride and a 26.2-mile marathon ...
New York, USA, March 03, 2025 (GLOBE NEWSWIRE) -- LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight LEQEMBI (lecanemab) has significant ...
US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...
LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatmen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback